|
|
| Line 1: |
Line 1: |
| - | <center>[[Image:Logo-si.jpg]]
| |
| - | [[Image:line-si4.jpg]]
| |
| - | <table cellpadding="10">
| |
| - | <tr><th>[[Ljubljana, Slovenia 2006/Background|Home]]</th>
| |
| - | <th>[[Background and Signalling Pathway]]</th>
| |
| - | <th>[[Proposal & Approach]]</th>
| |
| - | <th>[[Anticipated Results & Significance]]</th>
| |
| - | <th>[[Team members]]</th></tr></table>
| |
| - | [[Image:line-si3.jpg]]
| |
| - | </center>
| |
| | | | |
| - | <h1>Troubleshooting</h1>
| |
| - |
| |
| - | ''Luminometry''
| |
| - | Luminiscence cannot be measured in vivo since celentrazine is decays too quickly, many parallells and controls are needed and therefor few 396-well plates are used in which pattern of transfection stimulation is very complicated.
| |
| - |
| |
| - |
| |
| - | <h1>Terms</h1>
| |
| - |
| |
| - | <dl><dt>''Dominant negative protein''</dt>
| |
| - | <dd>A protein that is mutated in way that has only one domain, that interacts only with one protein in signaling pathway (in our example) upstream but not downstream. The result is blockade of pathway.</dd>
| |
| - |
| |
| - | <dt>''MyD88''</dt>
| |
| - | <dd>A protein at the beginning of our signaling pathway that transfer signal from TLR receptor to downstream proteins (IRAK4) resulting in NF-kappaB activation.</dd>
| |
| - |
| |
| - | <dt>''TRAF6''</dt>
| |
| - | <dd>A protein that functions as a signalling mediator which binds to IRAK1 and transfer signal downstream and also resulting in NF-kappaB activation.</dd>
| |
| - |
| |
| - | <dt>''NFκB''</dt>
| |
| - | <dd>A transcription factor that function as heterodimer NFκB dimers are usually sequestered in the cytoplasm in an inactive form by molecules of the inhibitor of NFκB (IκB). Activation of NFκB involves the phosphorylation and proteolysis of the IκB proteins, release and nuclear translocation of the NFκB, resulting in activation of NFκB-dependent transcription.</dd></dl>
| |
| - |
| |
| - | <h1>References</h1>
| |
| - |
| |
| - |
| |
| - | <h1>Sponsors</h1>
| |
| - |
| |
| - | {| border="0" cellspacing="0" cellpadding="5" align="center"
| |
| - | |[http://www.ki.si/ http://parts2.mit.edu/wiki/images/9/90/Logo_ki2.jpg]
| |
| - | |[http://www.lek.si/ http://parts2.mit.edu/wiki/images/0/09/Lek2.jpg]
| |
| - | |}
| |
| - |
| |
| - |
| |
| - | <h1>Donators</h1>
| |
| - | Krka pharmaceutical company,
| |
| - | Mediline
| |
| - |
| |
| - |
| |
| - |
| |
| - | <hr>
| |
| - | Komentarji:
| |
| - | - Terms bi se pojavljal kot 'floating bar' (predlagal Marko)
| |
| - | <hr>
| |
| - |
| |
| - | <center>
| |
| - | [[Image:line-si4.jpg]]
| |
| - | <table cellpadding="10">
| |
| - | <tr><th>[[Ljubljana, Slovenia 2006/Background|Home]]</th>
| |
| - | <th>[[Background and Signalling Pathway]]</th>
| |
| - | <th>[[Proposal & Approach]]</th>
| |
| - | <th>[[Anticipated Results & Significance]]</th>
| |
| - | <th>[[Team members]]</th></tr></table>
| |
| - | [[Image:line-si3.jpg]]
| |
| - | </center>
| |
